Addus HomeCare Corporation

▲ Bull Case

• ◆HCBS is politically protected and the market is mispricing the legislative outcome. Home- and community-based care costs $50,000–100,000 less per year than nursing home placement, giving governors bipartisan incentive to protect HCBS. If OBBBA passes with HCBS substantially protected, ~$20–30/share of risk premium embedded in current price evaporates, and ADUS re-rates from 10.3x to 12–13x EBITDA (~$120–135/share) within months.
• ◆FCF power is severely underappreciated; approaching $10/share by FY2030. ADUS generates $7.35 FCF/share at 7.4% FCF yield on a business growing FCF at 15%+ annually. FCF/share doubles from $5.74 (FY2026E) to $9.96 (FY2030E) in base case. Healthcare services compounders with this combination of yield and growth rate typically trade at 18–22x FCF, not 17x.
• ◆Gentiva integration is a multi-year, predictable margin earn-out story. Gentiva entered at ~8% EBITDA margin versus ADUS's 11% platform average. Applying ADUS's scheduling, compliance, and staffing technology to acquired operations should lift TX/Carolinas markets toward 10–11% EBITDA by FY2026–27, adding ~$8M incremental EBITDA from 3pp margin lift on ~$270M revenue before any volume growth.

▼ Bear Case

• ◆OBBBA Medicaid eligibility restrictions materially reduce addressable census. A 5% reduction in personal care census means ~$55M revenue headwind and ~$18M EBITDA impact. Combined with proposed 80/20 wage pass-through rule, bears model 200–400bp EBITDA margin compression, bringing FY2026E EBITDA from $183M to $139M and stock to $65–85.
• ◆Caregiver wage inflation will eventually outpace Medicaid rate pass-through. Five-year margin expansion (31.2% → 32.5%) depended on state rate increases keeping pace with minimum wage — a correlation not guaranteed forward. If wage inflation runs 4–5% while rates rise only 2–3%, gross margin compresses to 30–31%, eliminating ~$20–28M of annual EBITDA at FY2025 revenue scale.
• ◆Post-Gentiva organic growth of 7–8% does not justify premium multiple for regulated utility. Q1 2026 confirms ADUS is steady 7–8% grower post-acquisition-lapping—solid but not exceptional enough to command 12–14x EBITDA when 70%+ of revenue is government-reimbursement exposed. At 9–10x EBITDA (regulated-utility discount), stock falls to $85–100 even on base-case EBITDA.

“The debate is not about business quality—it is about the probability distribution of Medicaid policy outcomes. Fourteen analysts cover ADUS with average price target of $132.69 (34% upside). Bulls argue HCBS is structurally protected due to cost-effectiveness and bipartisan gubernatorial support; historical HCBS cuts at federal level are rare, and political economy of 'kicking grandma out of home care' is treacherous. Bears argue legislative risk is real and incremental; even if HCBS escapes worst of OBBBA, the 80/20 compensation rule alone could compress margins without rate offsets. NY CDPAP exit proves state-level regulatory changes can force market exits. Resolution: Q2/Q3 2026 earnings showing clean Gentiva integration plus Congressional OBBBA compromise weakening HCBS provisions = bull resolution. OBBBA passage with full restrictions plus Q2 earnings miss = bear resolution.”

• ◆Q2 2026 earnings (Aug): Gentiva same-store personal care growth ≥6%, adj. EBITDA margin ≥11.5% (65% probability; +10–15% impact)
• ◆OBBBA legislative outcome (H2 2026): HCBS exemption or watering-down via Congressional compromise (50% probability; +15–20% if bull case wins)
• ◆Capital structure inflection (Q4 2026): Net debt reaches zero, management announces buyback program (35% probability; +8–12% impact)
• ◆Strategic hospice acquisition ($75–100M, 2026–27): Accretively priced (45% probability; +5–10% near-term, +15% at 12 months)
• ◆Gentiva 2-year integration anniversary (Q1 2027): Acquired markets reach 10–11% EBITDA margin, proving integration thesis (70% probability; +8–12% re-rating validation)

• ◆OBBBA full Medicaid eligibility restrictions (>5% enrollment reduction): HIGH severity, 25% probability. Monitor HCBS exemption language and state implementation flexibility.
• ◆Caregiver wage inflation outpacing rate pass-through (2pp gross margin squeeze): HIGH severity, 30% probability. Watch quarterly gross margin <31.5% in Q2 2026 as red flag.
• ◆Illinois Medicaid rate freeze/cut >3% (IL = 30–35% of PC revenue): MEDIUM severity, 25% probability. Track IL state budget and HCBS restructuring risk.
• ◆Gentiva integration delay (same-store stagnation in TX/Carolinas): MEDIUM severity, 20% probability. Monitor personal care same-store by geography if disclosed.
• ◆Caregiver turnover spike / recruiting cost escalation: MEDIUM severity, 25% probability. Monitor headcount and direct cost ratio in SG&A disclosures.